MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Press releases

Stay current with the latest press releases from within the industry.

New Research Formula for Heart Disease with effective control over CRP levels.

Release issued 16th September 2009

According to American Heart Association, High levels of CRP consistently predict new coronary events in patients with unstable angina and acute myocardial infarction (heart attack). Research shows that people have heart attacks due to high levels of CRP; high levels of LDL cholesterol are also a major risk. Various studies have proved that statin is a drug of choice for patients with high CRP levels with or without elevated blood lipid levels However; statins have few important side effects. The most serious side effect is liver failure as it causes increase in liver enzymes and rhabdomyolysis which can impair kidney function & lead to kidney failure.
Considering all these facts Exotic Naturals has focused to develop a unique formula which helps to reduce CRP levels considerably and to improve quality of life. E - LL - 01 was developed because of intensive R&D process and intellectual knowledge of Exotic Team. Exotic naturals is proud to present E-LL-01 which has shown lipid lowering activity with reduction in CRP levels in 62 patient clinical studies.
An open label randomized study to compare the safety and efficacy of two doses of E-LL-01 in lowering blood lipids and reducing risk of myocardial infarction was conducted as per ICH-GCP guidelines. 62 patients with LDL > 160 mg/dl and/or Total Cholesterol > 240 mg/dl were given therapy of E-LL-01 as mono therapy for 12 weeks. Both the doses of E-LL-01 have shown significant reduction (P < 0.05) in LDL-C, VLDL-C, and Total Cholesterol at the end of the study as compared to baseline. There was 34% reduction in CRP levels in one group (C-Reactive Proteins) indicating reducing the risk of Ischemic heart diseases.
Exotic has developed products in some of the fastest growing health categories - Male Sexual Dysfunction, Lipid Lowering and Diabetes Type 2, Allergies, Insomnia, Osteoarthritis & Antioxidants and lots more at the R&D stage. Exotic Naturals is offering these exclusive opportunities to alliance partners for co-development and co-marketing worldwide.
For more information on Exotic Naturals & its products visit www.exoticnatural.com or contact Rekha Patel (bizdev@exoticnatural.com)
 

Company details

If you want to find out more about the company visit Exotic Naturals profile.

Latest Exotic Naturals press releases

More Press Releases

Related categories

Therapeutic target
Cardiovascular
Oral Health
Other therapeutic
Industry sector
Academic/Research
Drug discovery
Pharmaceutical

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
The countdown has started...
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us